Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

Eton, Omar; Ross, Merrick I; East, Mary Jo; Mansfield, Paul F; Papadopoulos, Nicholas; Ellerhorst, Julie A; Bedikian, Agop Y; Lee, Jeffrey E

doi:10.1186/1479-5876-8-9

Journal of Translational Medicine

Table 3 Individual Patient Clinical and Biomarker Data

From: Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

						Delayed Type Hypersensitivity (DTH)				γ-interferon ELISPOT*
					Dose Level	DNCB	HSPPC96	Autol. tumor	PBMC					OR	TTP	OS
M/F	Age	# prior	KPS	Stage**	μg	Grade***				BL	Wk 3	Wk 4	Wk 8		Months		Alive
TREATED WITH INDICATOR LESIONS PRESENT
F	53	4	80	4B	2.5	4	0	n/d	n/d	-0.3	0.5	-0.3	0.5	PD	1.6	21.3
M	36	2	80	4B	2.5	0	0	n/d	n/d	1.5	11.5	9.5	0.0	SD	1.6	35.0
M	56	1	80	4B	2.5	4	n/d	n/d	n/d	n/d	n/d	n/d	n/d	PD	1.9	2.4
M	56	3	90	4B	2.5	0	0	0	0	0.0	-1.7	-9.0	-2.3	PD	2.1	38.2
M	61	1	90	4B	2.5	3	0	n/d	n	2.5	6.0	5.3	13.3	PD	1.8	18.0
M	52	1	80	4B	2.5	0	0	0	0	n/d	n/d	n/d	n/d	PD	1.6	15.9
F	56	1	90	3N2C	25	0	0	0	0	0.3	-0.3	-1.3	0.3	PD	1.5	6.0
M	16	1	80	3N2C	25	0	0	0	0	2.0	21.5	14.7	1.8	PD	0.2	6.9
M	65	5	80	4B	25	3	0	n/d	n/d	n/d	n/d	n/d	n/d	PD	1.2	11.7
M	50	1	90	4B	25	4	0	0	0	n/d	n/d	n/d	n/d	PD	1.0	3.7
M	47	3	80	4B	25	0	0	0	0	n/d	n/d	n/d	n/d	PD	0.7	24.6
M	58	3	80	4B	25	4	0	0	0	0.0	0.0	0.0	0.0	PD	1.7	16.0
M	47	2	90	4B	25	0	0	n/d	n/d	0.5	-0.3	0.2	-1.7	SD	60.6	62.7
M	32	1	80	4A	100	0	0	0	0	n/d	n/d	n/d	n/d	PD	0.7	6.7
M	59	0	80	4B	100	3	0	0	0	-1.3	0.0	0.0	0.0	PD	4.4	24.0
M	76	0	80	4B	100	0	0	0	0	0.5	n/d	1.0	n/d	SD	14.6	15.5
TREATED IN THE ADJUVANT SETTING
F	63	1	80	3N2C	2.5	3	0	0	0	0.7	2.0	1.3	1.7	PD	4.0	12.3
M	47	1	90	3N1	2.5	3	0	n/d	n/d	0.0	1.0	1.0	0.0	NED	99.5	99.5	Alive
F	40	1	90	3N1	2.5	4	0	n/d	n/d	0.0	0.5	0.5	0.5	NED	101.1	101.1	Alive
M	64	1	80	3N2C	2.5	3	0	n/d	n/d	1.0	0.3	1.0	1.3	NED	110.5	110.5	Alive
M	52	1	90	4A	2.5	0	0	n/d	n	-10.7	12.7	7.3	0.0	NED	116.1	116.1	Alive
M	63	0	90	3N2C	25	3	0	0	0	1.0	-0.3	2.0	2.0	PD	1.6	20.4
M	59	1	90	3N2A	25	3	0	0	0	0.0	0.0	0.0		PD	8.1	18.2
M	63	1	90	3N2A	25	3	0	n/d	n/d	0.0	0.0	0.0	0.0	PD	26.7	30.9
F	70	3	90	4A	25	0	0	0	0	9.0	0.0	0.5	2.5	NED	110.3	110.3	Alive
M	46	1	80	4B	25	3	n/d	n/d	n/d	n/d	n/d	n/d	n/d	PD	1.7	14.4
F	55	1	90	4B	25	4	0	trace	0	n/d	n/d	n/d	n/d	PD	21.3	122.0	Alive
F	41	1	80	4B	25	4	0	0	0	0.0	0.3	0.0	0.0	PD	30.4	119.5	Alive
F	48	0	90	4B	25	3	0	0	0	-0.5	0.5	2.0	1.5	NED	68.8	68.8	Alive
M	44	4	80	4B	25	4	0	0	0	-2.3	13.3		-2.9	NED	116.1	116.1	Alive
M	58	0	90	3N2A	100	3	0	0	0	n/d	n/d	n/d	n/d	PD	27.6	41.9
F	43	0	90	3N2A	100	4	0	0	0	0.0	0.5	-1.0	-0.3	NED	30.1	30.1	Alive
M	65	2	90	4A	100	3	0	0	0	0.7	0.7	-5.3	-0.3	PD	27.8	119.7	Alive
M	56	1	80	4B	100	3	0	0	0	0.7	0.3	1.3	-0.3	PD	5.4	11.3
F	44	1	80	4B	100	0	0	0	0	n/d	n/d	n/d	n/d	PD	15.7	106.8	Alive
M	42	2	90	4B	100	2	0	0	0	14.3	8.3	8.7	14.3	NED	119.6	119.6	Alive

* Mean # spot forming PBMC producing γ-interferon (SFC) in the presence of autologous tumor cells, corrected for mean # SFC in the absence of tumor cells
** 1992 American Joint Commission on Cancer Staging System
*** For all time points (Baseline, week 4, week 8), DTH was Grade 0 for HSPPC-96, autologous tumor, PBMC in all patients tested
Abbreviations:
# prior Number prior regimens
OR Objective response
Autol. Autologous
OS Overall Survival
BL Baseline
PD Progression of Disease
KPS Karnofsky performance status
SD Stable Disease
M/F Male/Female
TTP Time to prtogression
n/d Not done
Wk Week
NED No evidence of recurrent disease (treated in the adjuvant setting)

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com